【摘 要】
:
[Baekgroud] Nomogram has demonstrated its capability in individualized estimates of survival in diverse cancers.To date, however, no nomogram has been developed for ESCC.[Methods] We retrospectively i
【机 构】
:
Cancer Research lnstitute,Zhejiang Cancer Hospital & Key Laboratory Diagnosis and Treatment Technolo
【出 处】
:
2014华东胸部肿瘤论坛暨第七届浙江省胸部肿瘤论坛
论文部分内容阅读
[Baekgroud] Nomogram has demonstrated its capability in individualized estimates of survival in diverse cancers.To date, however, no nomogram has been developed for ESCC.[Methods] We retrospectively investigated 1195 patients who underwent radical esophagectomy for ESCC at Zhejiang Cancer Hospital in Hangzhou, China.We randomly assigned two-thirds of the patients to a training cohort (n=797) and one-third to a validation cohort (n=398).Cox proportional hazards regression analysezis were performed using the training cohort,and a nomogram was constructed for predicting 3-year and 5-year overall survival.The discriminative ability of the nomogram was determined by the concordance index (Cindex) and calibration plot.The predictive accuracy of the nomogram was compared to that of the sixth and seventh editions of the TNM staging system according to the C-index.[Results] Multivariate analysis identified tumor length, surgical approach, number of examined lymph node, number of positive lymph node,extent of positive lymph node,grade,and depth of invasion as independent risk factors for survival.External validation shows that the nomogram exhibited a sufficient level of discrimination according to the C-index (0.715,95%CI=0.671~0.759).Calibration curve demonstrates that the nomogram predicted survival was in good agreement with the actual observation.The C-index of the nomogram was significantly higher than that of the sixth edition (0.664,P-value<0.0001) and the seventh edition (0.696, P-value<0.0003) of the TNM classification.[Conclusion] This study developed the first nomogram for ESCC that can be applied in daily clinical practice for individualized survival prediction.
其他文献
胸部放疗是局限期小细胞肺癌(small cell lung cancer,SCLC)综合治疗中不可缺少的部分.但放疗的靶区范围一直存在争议且未得到足够重视:纵隔淋巴结引流区应予选择性照射(elective nodal irradiation,ENI)还是可以采用累及野照射(involved field radiotherapy,IFRT)?对于诱导化疗后的患者,应该照射化疗前原发灶范围还是化疗后残
目的:据报道,miR-181a涉及机体免疫、新陈代谢、抑癌和促癌等多种途径.然而,miR-181a在低侵袭性的乳腺癌MCF-7细胞中对阿霉素敏感性的作用机制尚不清楚.本实验致力于研究miR-181a影响乳腺癌细胞对阿霉素药物敏感性的机制.方法:荧光定量PCR检测miR-181a在乳腺癌细胞MCF-7和MCF-7/ADR中的表达情况.使用Lipofectamine2000对2株细胞分别转染miR18
A nationwide multicenter retrospective study from 1999 to 2008 was performed in China.A total of 135 (3.2%) invasive lobular carcinoma (ILC) cases were compared with 3471(82.4%) invasive duetal carcin
目的:应用多参数流式细胞术检测乳腺癌患者外周血循环肿瘤细胞(Circulating Tumor Cells,CTC)分析其结果.方法:将SKBR-3乳腺癌细胞有限稀释后依次加到健康志愿者外周静脉血单个核细胞中,以评价本方法灵敏度.应用Moflo XDP超高速流式细胞仪对于62例女性乳腺癌及20例女性健康志愿者外周血EpCAM、CK18和CD45的表达情况进行研究,以循环肿瘤细胞(CTCs)数目≥5
目的:了解PAX6在乳腺癌组织中表达和临床病理因素及预后意义.方法:用免疫组织化学方法检测组织芯片上111例乳腺癌组织内PAX6蛋白表达状况,并分析PAX6与乳腺癌病理分级、TNM分期、患者预后等临床病理因素的相关性,对影响乳腺癌的生存因素进行Cox回归模型统计分析.结果:用Kaplan-meier单因素方法分析:PAX6染色强度++有38例,生存31例占81.6%;++~+++有37例,生存30
目的:分析2008~2010年永康市乳腺癌发病情况.方法:利用2008~2010年永康市社会保障局医保和农保的医疗资料中新发乳腺癌病例,以及永康市人民医院就诊的新发病肺市癌病人的发病数据,分析性别、年龄别和部位别乳腺癌的发病特点.结果:2008~2010年永康市恶性肿瘤新发病例4194例,乳腺癌新发病例290例,占6.91%.女性乳腺癌发病率为34.52/10万,中标率为23.84/10万,世标率
胸腺瘤是惰性生长但具有侵袭性的肿瘤。临床上少见,X线是最基本的检查,CT检查是诊断的最重要手段,PET检查对恶性程度的区分起一定的作用。手术仍是治疗胸腺瘤的最主要方法,新辅助化疗及术前放疗提高了胸腺肿瘤的手术切除率,可切除的胸腺瘤无论分期早晚都应争取全切,然后根据病理类型及临床分期来选择辅助治疗方案。完全切除、WHO组织学分类、Masaoka临床分期、化疗和放疗是影响远期效果的独立因素,对于不可切
目的:探讨直肠癌组织PI3K和Akt蛋白表达及与预后相关性.方法:应用免疫组织化学技术检测PI3K和Akt蛋白在60例直肠癌组织、30例直肠腺瘤组织及10例癌旁正常黏膜组织中的表达,并对60例直肠癌患者进行随访.结果:PI3K和Akt蛋白在直肠癌组织中高表达;两者呈正相关.PI3K蛋白表达水平与术前CEA水平、分化程度、临床分期、淋巴结转移和远处转移有关(P均<0.05);与年龄、性别、肿瘤部位和
To investigate whether MDR1 polymorphisms are associated with therapeutic outcome and hematologic toxicities of taxanes-based preoperative chemotherapy in breast cancer patients.MDR1 variants were det
Breast cancer is one of the most common malignancies in women worldwide.It was estimated that in the United States approximately 192,000 female patients would be diagnosed with breast cancer and 40,00